New bipolar drug MK-8189 passes early safety check in small study
NCT ID NCT06273774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a drug called MK-8189 in 34 adults with stable bipolar I disorder. Researchers monitored side effects and how the drug moved through the body. The goal was to see if the drug is safe enough for further testing, not to measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Center for Medical Research ( Site 0001)
Atlanta, Georgia, 30331, United States
-
Hassman Research Institute Marlton Site ( Site 0006)
Marlton, New Jersey, 08053, United States
-
Woodland International Research Group-Clinical Research ( Site 0009)
Little Rock, Arkansas, 72211, United States